<DOC>
	<DOCNO>NCT00710216</DOCNO>
	<brief_summary>This study examine effect telbivudine compare lamivudine early viral kinetics patient chronic hepatitis B . The virus Kinetics measure viral load ( HBV-DNA ) reduction serum first 12 week therapy .</brief_summary>
	<brief_title>Comparison Telbivudine Versus Lamivudine Early Dynamics Kinetics Viral Suppression Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Documented compensated HBeAgpositive negative chronic hepatitis B Increased viral load concentration serum HBVDNA least 10^4 copies/ml Proof inflammatory activity liver : ALT ≥ 2 x ULN histological evidence inflammatory activity ≥ level I fibrosis ≥ I degree ( accord Desmet classification ) Negative urine pregnancy test fertile woman Willingness use recognize method contraception Able comply study regimen provide write informed consent Current previous antiviral treatment chronic hepatitis B Nucleus ( ) id analoga Known hypersensitivity lamivudine telbivudine component preparation Pregnant breastfeed woman woman Simultaneous participation clinical trial past three month Coinfected HCV , HDV , HIV Other non HBVrelated chronic liver disease : Autoimmune hepatitis , primary biliary cirrhosis , Hemochromatosis , alpha1 antitrypsin deficiency , alcoholic hepatitis Evidence hepatocellular carcinoma ( alphafetoprotein level &gt; 100 ng/ml ) Active drug use , include excessive alcohol consumption last 6 month participate clinical trial Use systemic treatment antineoplastic immunomodulatory medication within last 6 month participate clinical trial duration clinical examination Lack willingness inability consent write Concurrent condition likely preclude compliance schedule evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Viral kinetics</keyword>
	<keyword>Viral dynamic</keyword>
	<keyword>Telbivudine</keyword>
	<keyword>Lamivudine</keyword>
</DOC>